Page 51 - Haematologica Vol. 107 - September 2022

REVIEW ARTICLE - IgM monoclonal gammopathies of clinical significance J. Khwaja et al.
response in patients with anti-MAG neuropathy: retrospective
study. Neurol Neuroimmunol Neuroinflamm. 2022;9(1):e1109.
54. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-
associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2016;10(10):CD002827.
55. Svahn J, Petiot P, Antoine JC, et al. Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. J Neurol Neurosurg Psychiatry. 2018;89(5):499-505.
56. Dalakas MC. Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies. Clin Exp Immunol.
1996;104 (Suppl 1):55-60.
57. Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain. 2000;123(Pt 4):710-717.
58. Le Cann M, Bouhour F, Viala K, et al. CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies. Blood. 2020;136(21):2428-2436.
59. Amaador K, Wieske L, Koel-Simmelink MJA, et al. Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy. J Neurol. 2022;269(7):3700-3705.
60. Minnema MC, Vos J, Eftimov F, Vrancken A. P-034: MAGNAZ trial - a prospective phase II study in patients with monoclonal gammopathy of unknown significance (MGUS) and anti-myelin associated glycoprotein (MAG) neuropathy and zanubrutinib treatment. Clin Lymphoma Myeloma Leuk. 2021;21(Suppl 2):S57.
61. Simon A, Asli B, Braun-Falco M, et al. Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy. 2013;68(5):562-568.
62. Jain T, Offord CP, Kyle RA, Dingli D. Schnitzler syndrome: an under-diagnosed clinical entity. Haematologica. 2013;98(10):1581-1585.
63. de Koning HD. Schnitzler's syndrome: lessons from 281 cases. Clin Transl Allergy. 2014;4:41.
64. Rowczenio DM, Pathak S, Arostegui JI, et al. Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome. Blood. 2018;131(9):974-981.
65. Lipsker D. The Schnitzler syndrome. Orphanet J Rare Dis. 2010;5:38.
66. Pathak S, Rowczenio DM, Owen RG, et al. Exploratory study of MYD88 L265P, rare NLRP3 variants, and clonal hematopoiesis prevalence in patients with Schnitzler syndrome. Arthritis Rheumatol. 2019;71(12):2121-2125.
67. Néel A, Henry B, Barbarot S, et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study. Autoimmun Rev. 2014;13(10):1035-1041.
68. Betrains A, Staels F, Vanderschueren S. Efficacy and safety of canakinumab treatment in Schnitzler syndrome: a systematic literature review. Semin Arthritis Rheum. 2020;50(4):636-642.
69. Krause K, Weller K, Stefaniak R, et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy. 2012;67(7):943-950.
70. Krause K, Feist E, Fiene M, Kallinich T, Maurer M. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol. 2012;129(3):848-850.
71. Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122(7):1114-1121.
72. Allain JS, Thonier F, Pihan M, et al. IGHV segment utilization in immunoglobulin gene rearrangement differentiates patients with anti-myelin-associated glycoprotein neuropathy from others immunoglobulin M-gammopathies. Haematologica. 2018;103(5):e207-e210.
73. Vos JM, Notermans NC, D'Sa S, et al. High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy. J Neurol Neurosurg Psychiatry. 2018;89(9):1007-1009.
74. Kyle RA, Benson J, Larson D, et al. IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):17-18.
75. Kyle RA, Benson JT, Larson DR, et al. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood. 2012;119(19):4462-4466.
76. Khwaja J, Patel AS, Arulogun SO, et al. IgM paraprotein- associated type 1 cryoglobulinaemia: clinical characteristics and outcomes. Blood. 2021;138(Suppl 1):4503-4503.
77. Nobile-Orazio E, Barbieri S, Baldini L, et al. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. Acta Neurol Scand. 1992;85(6):383-390.
Haematologica | 107 September 2022
2050